Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 18

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 18
---
 We will provide the specific terms of these securities in supplements to this prospectus, which will also describe the
specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before you invest. The aggregate
offering price of the securities we sell pursuant to this prospectus will not exceed $150,000,000.

The securities may be sold directly to
you, through agents or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of those securities
and the net proceeds we expect to receive from that sale will also be set forth in a prospectus supplement.

Our common stock is listed on
the Nasdaq Capital Market under the symbol “AADI.” Each prospectus supplement will indicate whether the securities offered thereby will be listed on any securities exchange. As of March 13, 2024, the aggregate market value of our
common stock held by our non-affiliates, as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately $40.5 million, based upon 16,637,988 shares of our outstanding common stock held by non-affiliates at the
per share price of $2.44, the closing sale price of our common stock on the Nasdaq Capital Market on March 4, 2024, the highest closing price of our common stock on the Nasdaq Capital Market during the preceding sixty day period. Pursuant to
General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our “public float” (the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0 million. We have not sold any securities in reliance on General Instruction I.B.6 of Form S-3 during the 12 calendar
months prior to and including the date of this prospectus.

Investing in our securities involves risks. Please carefully read the information under the headings “ Risk Factors” beginning on page 5 of this prospectus and “Item 1A – Risk Factors” of our most recent report on Form 10-Kor 10-Qthat is incorporated by reference in this prospectus before you invest in our securities.